Table 4 Insulin preparations (Cold-chain)
| Â | Â | Â | Â | Pre-Logistics Fee Regulation Prices | Post-Logistics Fee Regulation Prices | Â | Â | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Active Ingredients | O/G | Pack Size & Quantity | Ex- Man.Price in 2013 | Log Fee in 21013 | SEP in 2013 (VAT incl.) | Unit Price in 2013 | Logistics fee/SEP % | Logistics fee with proposed cap | SEP with proposed cap (VAT incl.) | Unit Price with proposed cap | Logistics fee with proposed cap/Sep % | Change in SEP after logistics fee cap | Overall effect on SEP after logistics fee cap |
Ultra-fast acting | |||||||||||||
Insulin Glulisine | O | 10/1 | 258.79 | 8 | 304.14 | 30.41 | 2.63 | 19.53 | 317.28 | 31.73 | 6.15 | 13.14 | Increase |
Insulin aspart | O | 10/1 | 223.63 | 30.19 | 289.36 | 28.94 | 10.44 | 17.42 | 274.79 | 27.48 | 6.34 | −14.57 | Decrease |
Insulin Lispro | O | 10/1 | 210.08 | 12.60 | 253.86 | 25.39 | 4.97 | 16.60 | 258.42 | 25.84 | 6.43 | 4.5694 | Increase |
Fast acting | |||||||||||||
Insulin (Dna) | O | 10/1 | 193.64 | 26.14 | 250.56 | 25.06 | 10.43 | 15.62 | 238.56 | 23.86 | 6.55 | −11.99 | Decrease |
Human Insulin | G | 5/1 | 240.25 | 19.22 | 295.79 | 59.16 | 6.49 | 18.41 | 294.87 | 58.97 | 6.244 | −0.92 | Decrease |
Regular Human Insulin (Rdna) | O | 10/1 | 210.08 | 12.60 | 253.86 | 25.39 | 4.97 | 16.60 | 258.42 | 25.84 | 6.43 | 4.56 | Increase |
Intermediate to long acting | |||||||||||||
Human Insulin | G | 5/1 | 240.25 | 19.22 | 295.79 | 59.16 | 6.49 | 18.41 | 294.87 | 58.97 | 6.244 | −0.92 | Decrease |
Isophane insulin | O | 10.1 | 233.46 | 31.52 | 302.07 | 30.21 | 10.43 | 18.01 | 286.67 | 28.67 | 6.28 | −15.40 | Decrease |
Isophane Human Insulin (Rdna) | O | 10/1 | 237.81 | 14.27 | 287.37 | 28.74 | 4.97 | 18.27 | 291.93 | 29.19 | 6.26 | 4.56 | Increase |
Long acting Insulin analogues | |||||||||||||
Insulin Glargine | O | 3/5 | 505.68 | 23.83 | 603.64 | 40.24 | 3.95 | 25.23 | 605.23 | 40.35 | 4.17 | 1.59 | Increase |
Insulin Detemir | O | 3/5 | 460.73 | 62.19 | 596.14 | 39.74 | 10.43 | 31.64 | 561.30 | 37.42 | 5.64 | −34.83 | Decrease |
Biphasic | |||||||||||||
Biosynthetic human insulin | O | 3/5 | 458.27 | 61.87 | 592.96 | 39.53 | 10.44 | 31.49 | 558.34 | 37.22 | 5.64 | −34.61 | Decrease |
Biosynthetic Human Insulin (30Â % Regular Insulin and 70Â % Isophane Insulin) | O | 3/5 | 349.13 | 22.29 | 423.41 | 28.23 | 5.26 | 24.95 | 426.45 | 28.43 | 5.85 | 3.04 | Increase |
Insulin (Human) | G | 3/5 | 321.71 | 15.28 | 384.17 | 25.61 | 3.98 | 23.30 | 393.31 | 26.22 | 5.92 | 9.14 | Increase |
Human Insulin/ isophane insulin | G | 5/1 | 235.21 | 18.82 | 289.59 | 57.92 | 6.49 | 18.11 | 288.79 | 57.76 | 6.27 | −0.80 | Decrease |
Biphasic Insulin analogues | |||||||||||||
75Â % Insulin Lispro Protamine Suspension (Npl) | O | 3/5 | 349.12 | 22.28 | 423.39 | 28.23 | 5.26 | 24.95 | 426.43 | 28.43 | 5.85 | 3.04 | Increase |
Insulin aspart | O | 3/5 | 417.34 | 56.34 | 539.99 | 35.99 | 10.43 | 29.040 | 508.87 | 33.92 | 5.71 | −31.12 | Decrease |
50Â % Insulin Lispro Protamine Suspension (Npl) | O | 3/5 | 349.12 | 22.28 | 423.39 | 28.23 | 5.26 | 24.95 | 426.43 | 28.43 | 5.85 | 3.04 | Increase |